About Amolyt Pharma
Amolyt Pharma is a company based in Ecully (France) founded in 2015 was acquired by Astrazeneca in March 2024. Amolyt Pharma has raised $292.31 million across 3 funding rounds from investors including Crédit Agricole, Astrazeneca and EQT. Amolyt Pharma offers products and services including Enhertu and Pertuzumab. Amolyt Pharma operates in a competitive market with competitors including MBX Biosciences, OMass Therapeutics, Spruce, Spruce Biosciences and Sigilon, among others.
- Headquarter Ecully, France
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Amolyt Pharma, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$292.31 M (USD)
in 3 rounds
-
Latest Funding Round
$137.49 M (USD), Series C
Jan 06, 2023
-
Investors
Crédit Agricole
& 22 more
-
Employee Count
Not available
-
Acquired by
Astrazeneca
(Mar 14, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Amolyt Pharma
Amolyt Pharma offers a comprehensive portfolio of products and services, including Enhertu and Pertuzumab.
Targets HER2-positive metastatic breast cancer treatment
Used in combination for breast cancer progression control
People of Amolyt Pharma
Unlock access to complete
Funding Insights of Amolyt Pharma
Amolyt Pharma has successfully raised a total of $292.31M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $137.49 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Amolyt Pharma
Amolyt Pharma has secured backing from 23 investors, including venture fund and institutional investors. Prominent investors backing the company include Crédit Agricole, Astrazeneca and EQT.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Locked | Locked | Locked | |
|
ICG is recognized as a global alternative asset manager.
|
Locked | Locked | Locked | |
|
Venture capital investments are made in life sciences companies.
|
Locked | Locked | Locked |
Investor details for Amolyt Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Amolyt Pharma
Investment portfolio details for Amolyt Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Amolyt Pharma
Detailed financials for Amolyt Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Amolyt Pharma Comparisons
Peer comparison for Amolyt Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Amolyt Pharma
Amolyt Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MBX Biosciences, OMass Therapeutics, Spruce, Spruce Biosciences and Sigilon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drugs for rare endocrine diseases are developed and advanced.
|
|
| Locked | Locked | Locked |
Proprietary mass spectrometry technologies are developed for protein assembly analysis.
|
|
| Locked | Locked | Locked |
Spruce is engaged in providing real estate closing services.
|
|
| Locked | Locked | Locked |
Rare HPA axis diseases are targeted by Spruce Biosciences' therapeutics.
|
|
| Locked | Locked | Locked |
Therapeutics for chronic diseases are developed via cell engineering platforms.
|
Detailed competitors of Amolyt Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Amolyt Pharma
Complete news archive for Amolyt Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Amolyt Pharma
Amolyt Pharma was founded in 2015 and raised its 1st funding round 4 years after it was founded.
Amolyt Pharma is headquartered in Ecully, France. It is registered at Ecully, Auvergne-rhone-alpes, France.
Amolyt Pharma is a funded company, having raised a total of $292.31M across 3 funding rounds to date.
Amolyt Pharma was established in 2015 in Ecully, France, within the biotechnology sector. Focus is placed on peptide-based therapeutics for rare endocrine and metabolic conditions. The pipeline includes eneboparatide, designed for hypoparathyroidism management, and AZP-3813, aimed at acromegaly treatment. Operations center on advancing these programs through research and development in the pharmaceutical field.
Amolyt Pharma's top competitors include MBX Biosciences, OMass Therapeutics and Spruce.
Amolyt Pharma offers Enhertu and Pertuzumab.
Amolyt Pharma has 23 investors. Key investors include Crédit Agricole, Astrazeneca, EQT, Eurazeo, and Orbimed.